Prof. Bhatt gives an in-depth overview of the REDUCE-IT trial, in which the effect of icosapent ethyl, a highly purified form of EPA, on CV outcomes was studied. WIth question to test your knowledge.
There is a spectrum of lipoproteins with different proportions of triglycerides and cholesterol. Jorge Plutzky talks about the biology of lipoproteins and why measuring only LDL-c is not sufficient to estimate lipid associated CV risk.
How can high levels of triglyceride-rich lipoproteins lead to myocardial infarction? Prof. Nordestgaard gives a presentation on mechanisms by which triglycerides can lead to CV events.
Steg outlines how epidemiological evidence pointed at TG as a CV risk factor, which was confirmed by genetic evidence and now further supported by interventional trial evidence.